{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:32:32Z","timestamp":1791513152347,"version":"4.3.4"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl. 5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2314,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The management of chronic hepatitis B currently rests with long-term therapy using oral nucleoside analogs. The major limitation of long-term therapy is antiviral resistance. Antiviral resistance is due to the high rate of mutations that can occur during hepatitis B virus (HBV) replication and the selection of these mutants due to a replication advantage in the presence of the antiviral agent. Indeed, high rates of antiviral resistance have been found with long-term use of lamivudine, in up to 76% of patients treated for 5 years or more. Rates of antiviral resistance are lower with adefovir therapy, \u02dc30% at 5 years. Newer more potent nucleoside analogs (tenofovir and entecavir) have proven to have much lower rates of antiviral resistance (&lt;1% after 2 years in treatment-na\u00efve subjects), but the long-term rates of resistance have yet to be fully defined. The appearance of these viral mutations (genotypic resistance) is usually followed by rises in HBV DNA levels (virological breakthrough) and then by rises in serum aminotransferase levels (biochemical breakthrough). The appearance of antiviral resistance can be accompanied by a transient but occasionally severe exacerbation of the underlying liver disease which in some instances has led to acute liver failure. Combinations of nucleoside analogs may offer an approach to preventing antiviral resistance, but the efficacy and safety of this approach have yet to be shown. A future research priority is to identify new agents active against HBV that target different steps in the viral life-cycle and might provide effective means to circumvent the antiviral resistance of nucleoside analogs. (Hepatology 2009;49:S174\u2013S184.)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.22900","type":"journal-article","created":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T08:31:18Z","timestamp":1278318678000},"page":"S174-S184","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":186,"title":["Antiviral resistance and hepatitis B therapy #"],"prefix":"10.1097","volume":"49","author":[{"given":"Marc G.","family":"Ghany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Doo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20241201","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","article-title":"Hepatitis B viruses: reverse transcription a different way.","volume":"134","author":"Nassal","year":"2008","journal-title":"Virus Res"},{"key":"R2-21-20241201","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.21364","article-title":"The halflife of hepatitis B virions.","volume":"44","author":"Murray","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R3-21-20241201","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/jhep.2000.18194","article-title":"The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.","volume":"32","author":"Richman","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R4-21-20241201","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/JVI.73.5.3616-3622.1999","article-title":"Enrichment of a precoreminus mutant of duck hepatitis B virus in experimental mixed infections.","volume":"73","author":"Zhang","year":"1999","journal-title":"J Virol"},{"key":"R5-21-20241201","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1128\/JVI.74.11.5257-5265.2000","article-title":"Low dynamic state of viral competition in a chronic avian hepadnavirus infection.","volume":"74","author":"Zhang","year":"2000","journal-title":"J Virol"},{"key":"R6-21-20241201","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/508550","article-title":"Toward a pharmacogenetic understanding of nucleotide and nucleoside analog toxicity.","volume":"194","author":"Hulgan","year":"2006","journal-title":"J Infect Dis"},{"key":"R7-21-20241201","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","article-title":"Management of antiviral resistance in patients with chronic hepatitis B.","volume":"9","author":"Locarnini","year":"2004","journal-title":"Antivir Ther"},{"key":"R8-21-20241201","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavirresistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-21-20241201","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management.","volume":"46","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R10-21-20241201","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/135965350801300317","article-title":"Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleosidenaive patients is not due to preexisting drugresistant mutants.","volume":"13","author":"CarroueeDurantel","year":"2008","journal-title":"Antivir Ther"},{"key":"R11-21-20241201","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.","volume":"34","author":"Yuen","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R12-21-20241201","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B.","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"R13-21-20241201","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2Year GLOBE Trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B.","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"R14-21-20241201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(05)81448-5","article-title":"Incidence and predictors of emergence of Adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB).","volume":"42","author":"Locarnini","year":"2005","journal-title":"J Hepatol"},{"key":"R15-21-20241201","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/AAC.43.8.1947","article-title":"Emergence of drugresistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.","volume":"43","author":"Zhou","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-21-20241201","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1172\/JCI11100","article-title":"The polymerase L528M mutation cooperates with nucleotide bindingsite mutations, increasing hepatitis B virus replication and drug resistance.","volume":"107","author":"Ono","year":"2001","journal-title":"J Clin Invest"},{"key":"R17-21-20241201","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.","volume":"27","author":"Allen","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R18-21-20241201","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.77.21.11833-11841.2003","article-title":"4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.","volume":"77","author":"Delaney","year":"2003","journal-title":"J Virol"},{"key":"R19-21-20241201","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Longterm safety of lamivudine treatment in patients with chronic hepatitis B.","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"R20-21-20241201","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/jhep.2000.19619","article-title":"Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.","volume":"32","author":"Nafa","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R21-21-20241201","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Entecavir resistance is rare in nucleoside naive patients with hepatitis B.","volume":"44","author":"Colonno","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R22-21-20241201","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"R23-21-20241201","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.","volume":"132","author":"Ghany","year":"2007","journal-title":"Gastroenterology"},{"key":"R24-21-20241201","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2008.10.008","article-title":"Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro crossresistance profile than the nucleotide analog inhibitors adefovir and tenofovir.","volume":"81","author":"Seifer","year":"2009","journal-title":"Antiviral Res"},{"key":"R25-21-20241201","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181VT mutants on hepatitis B treatment failure.","volume":"48","author":"Villet","year":"2008","journal-title":"J Hepatol"},{"key":"R26-21-20241201","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1128\/AAC.00239-06","article-title":"Emergence of a novel lamivudineresistant hepatitis B virus variant with a substitution outside the YMDD motif.","volume":"50","author":"Yatsuji","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-21-20241201","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1053\/jhep.2000.7296","article-title":"Clearance of the original hepatitis B virus YMDDmotif mutants with emergence of distinct lamivudineresistant mutants during prolonged lamivudine therapy.","volume":"31","author":"Yeh","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R28-21-20241201","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/AAC.45.1.138-144.2001","article-title":"Molecular modeling approach to understanding the mode of action of Lnucleosides as antiviral agents.","volume":"45","author":"Lee","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-21-20241201","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/JVI.75.10.4771-4779.2001","article-title":"Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).","volume":"75","author":"Das","year":"2001","journal-title":"J Virol"},{"key":"R30-21-20241201","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0168-8278(00)80284-6","article-title":"Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.","volume":"33","author":"Gutfreund","year":"2000","journal-title":"J Hepatol"},{"key":"R31-21-20241201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A oneyear trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"R32-21-20241201","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States.","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"R33-21-20241201","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Longterm lamivudine therapy reduces the risk of longterm complications of chronic hepatitis B infection even in patients without advanced disease.","volume":"12","author":"Yuen","year":"2007","journal-title":"Antivir Ther"},{"key":"R34-21-20241201","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAgnegative chronic hepatitis B.","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"R35-21-20241201","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa2a alone, lamivudine alone, and the two in combination in patients with HBeAgnegative chronic hepatitis B.","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"R36-21-20241201","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2036.2006.02806.x","article-title":"Lamivudine monotherapy in HBeAgnegative chronic hepatitis B: prediction of responsebreakthrough and longterm clinical outcome.","volume":"23","author":"Manolakopoulos","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-21-20241201","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs.","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"R38-21-20241201","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"R39-21-20241201","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"4th. In vitro susceptibility of adefovirassociated hepatitis B virus polymerase mutations to other antiviral agents.","volume":"12","author":"Qi","year":"2007","journal-title":"Antivir Ther"},{"key":"R40-21-20241201","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J Hepatol"},{"key":"R41-21-20241201","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa051214","article-title":"Variant of hepatitis B virus with primary resistance to adefovir.","volume":"354","author":"Schildgen","year":"2006","journal-title":"N Engl J Med"},{"key":"R42-21-20241201","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1086\/522521","article-title":"Hepatitis B virus containing the I233V mutation in the polymerase reversetranscriptase domain remains sensitive to inhibition by adefovir.","volume":"196","author":"Curtis","year":"2007","journal-title":"J Infect Dis"},{"key":"R43-21-20241201","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Longterm therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years.","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"R44-21-20241201","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B.","volume":"48","author":"Marcellin","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R45-21-20241201","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R46-21-20241201","first-page":"370A","article-title":"Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAgnegative patients with chronic hepatitis B (Study 102), preliminary analysis. Abstract.","volume":"48","author":"Marcellin","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R47-21-20241201","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.41.7.1444","article-title":"Identification of BMS200475 as a potent and selective inhibitor of hepatitis B virus.","volume":"41","author":"Innaimo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R48-21-20241201","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.22211","article-title":"Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.","volume":"47","author":"Baldick","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R49-21-20241201","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1128\/JVI.02395-06","article-title":"Inhibition of hepatitis B virus polymerase by entecavir.","volume":"81","author":"Langley","year":"2007","journal-title":"J Virol"},{"issue":"Suppl","key":"R50-21-20241201","first-page":"245A","article-title":"Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy. Abstract.","volume":"40","author":"Warner","year":"2005","journal-title":"HEPATOLOGY"},{"issue":"Suppl","key":"R51-21-20241201","first-page":"245A","article-title":"Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Abstract.","volume":"40","author":"Tenney","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R52-21-20241201","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAgpositive chronic hepatitis B.","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"R53-21-20241201","first-page":"302","article-title":"Entecavir at five years shows longterm maintenance of high genetic barrier to hepatitis B virus resistance.","volume":"2","author":"Tenney","year":"2008","journal-title":"Hepatol Int"},{"key":"R54-21-20241201","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudinerefractory, HBeAgpositive chronic hepatitis B.","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"R55-21-20241201","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"R56-21-20241201","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during longterm lamivudine therapy.","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"key":"R57-21-20241201","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R58-21-20241201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R59-21-20241201","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B.","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"R60-21-20241201","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","article-title":"AsianPacific consensus statement on the management of chronic hepatitis B: a 2005 update.","volume":"25","author":"Liaw","year":"2005","journal-title":"Liver Int"},{"key":"R62-21-20241201","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2004.01.006","article-title":"Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments.","volume":"40","author":"Hong","year":"2004","journal-title":"J Hepatol"},{"key":"R63-21-20241201","doi-asserted-by":"crossref","first-page":"10747","DOI":"10.1128\/JVI.01827-07","article-title":"Minority human immunodeficiency virus type 1 variants in antiretroviralnaive persons with reverse transcriptase codon 215 revertant mutations.","volume":"82","author":"Mitsuya","year":"2008","journal-title":"J Virol"},{"key":"R64-21-20241201","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/hep.20939","article-title":"Adefovir rapidly suppresses hepatitis B in HBeAgnegative patients developing genotypic resistance to lamivudine.","volume":"42","author":"Lampertico","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R65-21-20241201","first-page":"693A","article-title":"Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine resistant patients with HBeAg negative chronic hepatitis B. Abstract.","volume":"44","author":"Lapertico","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R66-21-20241201","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.21534","article-title":"Addingon versus switchingto adefovir therapy in lamivudineresistant HBeAgnegative chronic hepatitis B.","volume":"45","author":"Rapti","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R67-21-20241201","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","article-title":"A doseranging study of the efficacy and tolerability of entecavir in Lamivudinerefractory chronic hepatitis B patients.","volume":"129","author":"Chang","year":"2005","journal-title":"Gastroenterology"},{"key":"R68-21-20241201","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350501000507","article-title":"4th. Crossresistance testing of nextgeneration nucleoside and nucleotide analogs against lamivudineresistant HBV.","volume":"10","author":"Yang","year":"2005","journal-title":"Antivir Ther"},{"key":"R69-21-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B.","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"R70-21-20241201","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudineresistant hepatitis B virus infection.","volume":"40","author":"van Bommel","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R72-21-20241201","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.22323","article-title":"Entecavir therapy for lamivudinerefractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.","volume":"48","author":"Sherman","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R73-21-20241201","first-page":"270A","article-title":"First multicenter evaluation of the efficacy of tenofovir in nucleoside analog experienced patients with HBV monoinfection. Abstract.","volume":"46","author":"Van Bommel","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R74-21-20241201","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","article-title":"Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.","volume":"41","author":"Brunelle","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R75-21-20241201","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","article-title":"Tenofovir for patients with lamivudineresistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.","volume":"44","author":"van Bommel","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R76-21-20241201","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.","volume":"46","author":"Villet","year":"2007","journal-title":"J Hepatol"},{"key":"R77-21-20241201","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/MEG.0b013e3282f793d6","article-title":"Selection of an entecavirresistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.","volume":"20","author":"Leemans","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R78-21-20241201","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.21290","article-title":"Evolution of multidrug resistant hepatitis B virus during sequential therapy.","volume":"44","author":"Yim","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R79-21-20241201","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","article-title":"Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAgpositive chronic hepatitis B.","volume":"48","author":"Sung","year":"2008","journal-title":"J Hepatol"},{"key":"R80-21-20241201","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/hep.21939","article-title":"Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5year ideal response.","volume":"46","author":"Yuen","year":"2007","journal-title":"HEPATOLOGY"},{"key":"RU81-21-20241201","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","article-title":"Efficacy of lamivudine in patients with hepatitis B e antigennegativehepatitis B virus DNApositive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.","volume":"29","author":"Tassopoulos","year":"1999","journal-title":"HEPATOLOGY"},{"key":"RU82-21-20241201","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hep.1840400418","article-title":"Clinical outcome of HBeAgnegative chronic hepatitis B in relation to virological response to lamivudine.","volume":"40","author":"Di Marco","year":"2004","journal-title":"HEPATOLOGY"},{"key":"RU83-21-20241201","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B.","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"RU84-21-20241201","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigennegative chronic hepatitis B.","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22900","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T08:10:39Z","timestamp":1733040639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":82,"journal-issue":{"issue":"Suppl. 5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22900","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}